Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

MLA

Santoro, Mm, et al. “Drug-Resistance Development Differs between HIV-1-Infected Patients Failing First-Line Antiretroviral Therapy Containing Nonnucleoside Reverse Transcriptase Inhibitors with and without Thymidine Analogues.” HIV Medicine, vol. 14, no. 9, Oct. 2013, pp. 571–77. EBSCOhost, https://doi.org/10.1111/hiv.12044.

APA

Santoro, M., Sabin, C., Forbici, F., Bansi, L., Dunn, D., Fearnhill, E., Boumis, E., Nicastri, E., Antinori, A., Palamara, G., Callegaro, A., Francisci, D., Zoncada, A., Maggiolo, F., Zazzi, M., Perno, C., Ceccherini, S. F., & Mussini, C. (2013). Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Medicine, 14(9), 571–577. https://doi.org/10.1111/hiv.12044

Chicago

Santoro, Mm, C Sabin, F Forbici, L Bansi, D Dunn, E Fearnhill, E Boumis, et al. 2013. “Drug-Resistance Development Differs between HIV-1-Infected Patients Failing First-Line Antiretroviral Therapy Containing Nonnucleoside Reverse Transcriptase Inhibitors with and without Thymidine Analogues.” HIV Medicine 14 (9): 571–77. doi:10.1111/hiv.12044.